Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18328213 | 1.00 | KYNU (0.63) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL21362719 | 0.89 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL13369139 | 0.89 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL13625105 | 0.89 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL7518958 | 0.88 | PPARA (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL38660952 | 0.88 | PPARA (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL6940198 | 0.88 | PPARA (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL24130581 | 0.87 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL24130582 | 0.87 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL6498057 | 0.87 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| CN-116745283-A | Heterocyclic derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | KYNU 1983/4885ALDH1A1 2383/4885ALOX15 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.